DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
Rockville MD 20857

2036 7 MAR 29 A9:43

MAR 26 2007

Jeffrey Chasnow
Emily Marden
Pfizer Inc.
235 East 42nd Street
New York, NY 10017-5755

Re: Docket No. 2006P-0406/CP1

Dear Mr. Chasnow and Ms. Marden:

I am writing to inform you that the Food and Drug Administration (FDA) has not yet resolved the issues raised in your citizen petition received on October 5, 2006. Your petition asserts that the generic azithromycin for oral suspension drug product marketed by Pliva, Inc. (Pliva) appears to be misbranded because the drug product's label incorrectly identifies the polymorphic form of the active ingredient contained in the product. You request that FDA therefore take appropriate remedial action against the alleged misbranding of this product and reexamine Pliva's abbreviated new drug application for azithromycin for oral suspension to ensure its completeness and accuracy with respect to the active ingredient.

FDA has been unable to reach a decision on your petition because it raises complex issues requiring extensive review and analysis by Agency officials. This interim response is provided in accordance with FDA regulations on citizen petitions (21 CFR 10.30(e)(2)). We will respond to your petition as soon as we have reached a decision on your request.

Sincerely,

Jane A. Axelrad

Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

2006P-0406

LET 1